Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Corcept Therapeutics Incorporated (CORT) operate in?
Corcept Therapeutics Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Corcept Therapeutics Incorporated (CORT) current stock price?
As of the latest data, Corcept Therapeutics Incorporated stock price is $111.33, with a previous close of $110.51. Corcept Therapeutics Incorporated gained $0.82 in the last trading session, representing a 0.74% increase.
What is Corcept Therapeutics Incorporated (CORT) current market capitalization?
Corcept Therapeutics Incorporated market cap is approximately 12.03 billion.
What is Corcept Therapeutics Incorporated (CORT) Earnings Per Share (EPS)?
The trailing EPS is $0.45, and the forward EPS is $4.27.
What is Corcept Therapeutics Incorporated (CORT) Price-to-Earnings (P/E) ratio?
Corcept Therapeutics Incorporated current P/E ratio is 247.4, with a forward P/E of 26.07.
What is Corcept Therapeutics Incorporated (CORT) EBITDA?
Corcept Therapeutics Incorporated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 46.79 million.
Does Corcept Therapeutics Incorporated (CORT) pay dividends?
No. Corcept Therapeutics Incorporated does not pay a dividend.
How did Corcept Therapeutics Incorporated (CORT) perform in its most recent earnings report?
In the last report (June 30, 2026), Corcept Therapeutics Incorporated posted an EPS surprise of 1,000% and a revenue surprise of 16.41%.
What is Corcept Therapeutics Incorporated (CORT) beta (volatility) score?
Corcept Therapeutics Incorporated has a beta of 0.455, indicating lower volatility than the overall market.
